Meet IAG’s Bio-Partnering Team at Bio Europe, October 26-29, 2020
Meet IAG’s Bio-Partnering Team at the European biotech week!
IAGs’ team will attend BIO Europe 2020, October 26-29, 2020.
Dr. Diana Dupont-Roettger, Chief Scientific Alliances Officer and David Chia, Head of Bio-Partnering will attend the conference to support IAG’s portfolio companies and to expand IAG’s partnerships with clinical stage biotechnology and pharma companies seeking support in development of novel treatments to address unmet patient needs.
‘We see an increasing demand for an expert driven targeted development strategy, that brings together smart use of technology, advanced imaging and AI. We closely work with our partners enabling them to de-risks clinical R&D process and increase chances of success,’ said Dr. Diana Dupont-Roettger of IAG.
IAG, Image Analysis Group is the imaging expert company and industry’s trusted partner, operating through Strategy, Trial Solutions and Bio-Partnering divisions since 2007. IAG’s mission is to make a difference to the millions of patients needing better treatments fast.
We are building a diversified portfolio of innovative life science companies at various stages of clinical development. To date, IAG’s team announced partnerships with 9 biotechnology and 2 blue-chip pharma companies, involving risk-sharing development models and have seen one successful exit.
Bio-Partnering division of IAG works closely with investment and biotech communities and supports studies and projects seeking involvement of IAG’ expert team and advisors to bring additional value and increase chances of success.
Meet our team if you are interested to discuss:
- Development of clinical stage assets in areas of IAG’s therapeutic focus.
- IP acquisition from the academic partners and biotech companies
- Investment partnerships
- Strategic collaborations
Contact us via the Partnering system or email to <email@example.com>
‘By bringing strategic collaborators and smart investments, IAG supports drug development efforts through clinical trials to market entry’, said David Chia, IAG’s Head of Bio-Partnering, ‘Our Bio-Partnering team has signed 12 successful partnerships with blue-chip pharma companies, public and private biotechnology players and we are looking forward to extending this list’.
About IAG, Image Analysis Group
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development, and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com
About IAG’s Bio-Partnering
IAG’s Bio-Partnering is an independent division of IAG. Our biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships. We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, rheumatology, musculoskeletal, immunology markets.